Bias and trials stopped early for benefit [3]

JAMA

Volumn 304, Issue 2, 2010, Pages 157-158

  Korn, Edward L ^a   Freidlin, Boris ^a   Mooney, Margaret ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL RESEARCH; HUMAN; LETTER; PRIORITY JOURNAL; SAMPLE SIZE; STUDY DESIGN; EPIDEMIOLOGY; ETHICS; NEOPLASM; NOTE; RANDOMIZED CONTROLLED TRIAL; STATISTICS; TREATMENT OUTCOME;

BIAS (EPIDEMIOLOGY); NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SAMPLE SIZE; TREATMENT OUTCOME;

EID: 77954578141     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2010.932     Document Type: Letter

References (5)

1. Bassler D, Briel M, Montori VM, et al; STOPIT-2 Study Group. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA. 2010;303(12):1180-1187.
2. Cooper JS, Guo MD, Herskovic A, et al; Radiation Therapy Oncology Group. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). JAMA. 1999;281(17):1623-1627.
3. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-1684.
4. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al; FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354(8):809-820.
5. Goldberg RM, Sargent DJ, Morton RF, et al. Randomized controlled trial of reduced- dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. J Clin Oncol. 2006;24(21):3347-3353.